breast disease histopathology Flashcards

1
Q

What does normal breast tissue look like histologically

A

SS,
•Modified sweat glands
•Non-functional except during lactation
•Lobules = acini and intralobular stroma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What psysiological changes are seen in breast tissue prepubertally?

A
  • Prepubertal breast –few lobules (before puberty male and female breasts are identical)
  • Menarche –increase in number of lobules, increased volume of interlobular stroma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What psysiological changes are seen in breast tissue in a woman of childbearing age?

A

•Menstrual cycle
–follicular phase lobules quiescent, after ovulation cell proliferation and stromal oedema, with menstruation see decrease in size of lobules
•Pregnancy
–increase in size and number of lobules, decrease in stroma, secretory changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What does breast tisssue look like in pregnancy?

A

ss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What phsyiological changes are seen in breast tissue with increasing age?

A

Cessation of lactation
–atrophy of lobules but not to former levels
•Increasing age
–terminal duct lobular units (TDLUs) decrease in number and size, interlobular stroma replaced by adipose tissue (mammograms easier to interpret)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How can breast conditions present?

A
  • Pain
  • Palpable mass
  • Nipple discharge
  • Skin changes
  • Lumpiness
  • Mammographic abnormalities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which breast conditions can cause pain?

A

•May be cyclical and diffuse, in which case often physiological
•Non-cyclical and focal
–ruptured cysts, injury, inflammation
•Occasionally presenting complaint in breast cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which breast conditions can cause a palpable mass?

A
•Causes include:
–Normal nodularity
–Invasive carcinomas
–Fibroadenomas
–Cysts
•Most worrying if hard, craggy and fixed
•No woman should be allowed to have a lump in the breast without a firm diagnosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which breast conditions can cause nipple discharge

A

•Milky
–endocrine disorders e.g. pituitary adenoma; side effect of medication e.g., OCP
•Bloody or serous
–benign lesions e.g. papilloma, duct ectasia; occasionally malignant lesions
•Most concerning if spontaneous and unilateral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which breast conditions can cause mammographic abnormalities?

A

•Worrying findings include densities and calcifications
–Densities –invasive carcinomas, fibroadenomas, cysts
–Calcifications
–ductal carcinoma in situ (DCIS), benign changes
•Found during mammographic screening
•Women between 47-73 years invited every 3 years
•Easier to detect lesions in breasts of older women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Are breast conditions common?

A

Breast symptoms and signs are common
•Most breast symptoms and signs will be benign
•Fibroadenoma most common benign tumour
•Breast cancer most common non-skin malignancy in women
•Mammographic screening increases detection of small invasive tumours and in situ carcinomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How common are fibroadenomas

A

•Fibroadenomas

–Can occur at any age during reproductive period–Often <30 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How common are Phyllodes tumours

A

Phyllodes tumours

–Most present in 6thdecad

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How common is breast cancer

A
•Breast cancer
–Rare before 25 years (except for some familial cases)
–Incidence rises with age
–77% occurs in women >50 years
–Average age at diagnosis is 64 years
–In UK:
•45,500 new female cases and 300 new male cases a year
•12,500 deaths per year
  • Accounts for 20% of all malignancies in women
  • 1 in 12 women will develop breast cancer at some time in their life
  • Approximately 95% are adenocarcinomas
  • Other malignant tumours of the breast are very rare, e.g., primary sarcomas such as angiosarcoma
  • Most common in the upper outer quadrant (approximately 50% occur here)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How do we classify pathological conditions of the rbeast

A
  • Disorders of development
  • Inflammatory conditions
  • Benign epithelial lesions
  • Stromal tumours
  • Gynaecomastia
  • Breast carcinoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What disorders of development can be seen

A

E.g., milk line remnants -polythelia, accessory axillary breast tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What inflammtory conditions can be seen

A

•Acute mastitis–Almost always occurs during lactation–Usually Staphylococcus aureus infection from nipple cracks and fissures
–Erythematous painful breast, often pyrexia
–May produce breast abscesses
–Usually treated by expressing milk and antibiotics

•Fat necrosis
–Presents as a mass, skin changes or mammographic abnormality
–Often history of trauma or surgery
–Can mimic carcinoma clinically and mammographically

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What benign epithelial lesions can be seen?

A

•Fibrocystic change–Commonest breast lesion
–May present as a mass or mammographic abnormality
–Mass often disappears after fine needle aspiration (FNA)
–Histology
–cyst formation, fibrosis and apocrine metaplasia
–Can mimic carcinoma clinically and mammographically

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Describe the appearence of fibrocystic change

A

ss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What stromal tumours can be seen?

A

•Stromal tumours –e.g., fibroadenoma, phyllodestumours, lipoma, leiomyoma, hamartoma
•Fibroadenomas
–Present with a mass, usually mobile, or mammographic abnormality
–‘Breast mouse’
–mobile and elusive
–Can be multiple and bilateral
–Can grow very large and replace most of the breast
–Macroscopically -well circumscribed, rubbery, greyish/white
–Histology -composed of a mixture of stromal and epithelial elements
–Can mimic carcinoma clinically and mammographically
–Localised hyperplasia rather than true neoplasm

21
Q

What do fibroadenomas look like?

A

ss

22
Q

What are phyllodes tumours?

A

–Rare before 40 years old–Present as masses or as mammographic abnormalities
–Benign, borderline and malignant types; most benign, less than 5% malignant
–Can be very large and involve entire breast
–Histology:
•Nodules of proliferating stroma covered by epithelium (phullon = leaf)
•Stroma more cellular and atypical than that in fibroadenomas
–Need to be excised with wide margin or may recur
–Malignant type behave aggressively, recur locally and metastasize by blood stream

23
Q

What do phyllodes tumours look like

A

ss

24
Q

How common is male breast cancer

A

•Male breast cancer
–1% of all cases of breast cancer
–Increased risk with Klinefelter’s syndrome, male to female transsexuals, men treated with oestrogen for prostate cancer

25
Q

What are the hormone related risk factors for breast cancer

A

•Major risk factors are related to hormone exposure
–Gender
–Uninterrupted menses
–Early menarche (< 11 years)
–Late menopause
–Reproductive history -parity and age at first full term pregnancy
–Breast-feeding
–Obesity and high fat diet
–Exogenous oestrogens –HRT slightly increases risk (1.2-1.7 times), long term users of OCP possibly have an increased risk

26
Q

What are other risk factors for breast cancer

A

•Geographic influence
–Higher incidence in US and Europe
–Possible explanations include diet, physical activity, breast-feeding, environmental factors
•Atypical changes on previous biopsy (4-5 times)
•Previous breast cancer (10 times)
•Radiation
–Increased risk with previous exposure to therapeutic radiation (especially in childhood or adolescence), e.g. mantle radiation for Hodgkin’s lymphoma

Genetic

27
Q

Describe herediaty breast cancer

A

Hereditary breast cancer
–10% of breast cancers
–3% of all breast cancers and 25% of familial cancers attributed to mutations in BRCA1 (BReastCAncerassociated gene 1) or BRCA2
•Both tumour suppressor genes –their proteins repair damaged DNA
•0.1% of population has BRCA1 germline mutations
•Lifetime breast cancer risk for female carriers is 60-85%
•Median age at diagnosis is approximately 20 years earlier than sporadic cases
•Carriers may undergo prophylactic mastectomies
–Another gene involved in hereditary breast cancer is p53 (Li-Fraumenisyndrome)

28
Q

How do we classify breast carcinoma

A
  • Carcinomas divided into in situ and invasive

* Carcinomas can be ductal or lobular

29
Q

What is in situ carcinoma

A
  • Neoplastic population of cells limited to ducts and lobules by basement membrane (BM), myoepithelial cells are preserved
  • Does not invade into vessels and therefore cannot metastasise or kill the patien
30
Q

Why id DCIS a problem

A
  • Non-obligate precursor of invasive carcinoma
  • Most often presents as mammographic calcifications (clusters or linear and branching) but can present as a mass
  • Can spread through ducts and lobules and be very extensive
  • Histologically often shows central (comedo) necrosis with calcification
31
Q

What does DCIS look like

A

ss

32
Q

What is Paget’s disease

A

Cells can extend to nipple skin without crossing BM = Paget’s disease
–Unilateral red and crusting nipple
–Eczematous or inflammatory conditions of the nipple should be regarded as suspicious and biopsy performed to exclude Paget’s disease

33
Q

How does invasive carcinoma differ from DCIS

A

Neoplastic cells have invaded beyond BM into stroma
•Can invade into vessels and can therefore metastasize to lymph nodes and other sites
•Usually presents as a mass or as mammographic abnormality
•By the time a cancer is palpable more than half of the patients will have axillary lymph node metastases•Peaud’orange–involvmentof lymphatic drainage of skin

34
Q

What are skin changes in breast cancer

A

Pulling in, peau d’orange

35
Q

How is invasive breast cancer classified

A

•Invasive ductal carcinoma, no special type (IDC NST)
–70-80%
–Well-differentiated type –tubules lined by atypical cells
–Poorly differentiated type –sheets of pleomorphic cells
–35-50% 10 year survival

•Invasive lobular carcinoma
–5-15%
–Infiltrating cells in a single file, cells lack cohesion
–Similar prognosis to IDC NST
•Other types, e.g. tubular (1-2%, excellent prognosis), mucinous (1-6%, excellent prognosis, often older women)

36
Q

What does invasive breast carcinoma look like?

A

s

37
Q

What does mucinous carcinoma look like

A

s

38
Q

How does breast cancer spread

A
  • Lymph nodes via lymphatics–usually in the ipsilateralaxilla
  • Distant metastases via blood vessels –bones (most frequent site), lungs, liver, brain
  • Invasive lobular carcinoma can spread to odd sites –peritoneum, retroperitoneum, leptomeninges, gastrointestinal tract, ovaries, uterus
39
Q

What does vascular invasion look liek

A

s

40
Q

What factors determine prognosis in breast canecr

A
In situ disease or invasive carcinoma
•Tumour stage:
–Tumour size and locally advanced disease –invading into skin or skeletal muscle 
–Lymph Node metastases
–Distant Metastases
  • Tumour grade
  • Histologic subtype –IDC NST has poorer prognosis
  • Molecular classification and gene expression profile
41
Q

How does tumour grade affect survuval

A

ss

42
Q

What is molecular classification in breast cancer?

A

Oestogen receptor positive vs oestrogen receptor negative
Each split into her2 pos or neg
ss

43
Q

What is a gene expression profile and why is it important in breast cancer?

A
  • Microarrays have been used to examine the expression patterns of some 25,000 genes in tissues from breast cancer patients.
  • Computer cluster analysis of the patterns led to the identification of about 17 marker genes that can correctly identify about 90% of women who would eventually develop metastases.
44
Q

How do we investigate and diagnose breast cancer?

A

•Triple approach
–Clinical –history, family history, examination
–Radiographic imaging –mammogram and ultrasound scan
–Pathology –core biopsy and fine needle aspiration cytology (FNAC)

45
Q

What is mammographic screening

A
  • Started in the UK in the late 1980s
  • Women 47–73 years
  • 2 view mammograms every 3 years
  • Aim is to detect small impalpable cancers and pre-invasive cancer (incidence of DCIS has increased from 5% of breast cancers to 25% in screened populations)
  • Look for asymmetric densities, parenchymal deformities, calcifications
  • Assess abnormalities using further imaging, core biopsy and FNAC
46
Q

What is local/regional control?

A

•Local and regional control
–Breast surgery –mastectomy or breast conserving surgery –decision depends on patient choice, size and site of tumour, number of tumours, size of breast
–Axillary surgery –extent depending on whether there are involved nodes (sentinel node sampling or axillary dissection)
–Post-operative radiotherapy to chest and axilla

47
Q

What is sentinel lymph node biopsy

A
  • Reduces the risk of postoperative morbidity
  • Intraoperative lymphatic mapping with dye and/or radioactivity of the draining or ‘sentinel’ lymph node(s) –the one most likely to contain breast cancer metastases
  • If the sentinel node(s) is negative axillary dissection can be avoided
48
Q

What are the therapeutic approaches in breast canecr

A

•Systemic control
–Chemotherapy –if benefits thought to outweigh the risks; if given before surgery = neoadjuvant
–Hormonal treatment, e.g. tamoxifen –depending on oestrogen receptor status (approximately 80% of cancers are ER positive)
–Herceptin treatment –depending on Her2 receptor status (approximately 20% of cancers are Her2 positive)
•Her2 is a member of the human epidermal growth factor receptor family
•Encodes a transmembrane tyrosine kinase receptor
•Herceptin = trastuzumab= humanised monoclonal antibodies against the Her2 protein

49
Q

Jow do we improve survival from breast cancer

A

Early detection –awareness of disease, importance of family history, self-examination, mammographic screening
•Neoadjuvant chemotherapy –early treatment of metastatic disease
•Use of newer therapies –e.g. Herceptin
•Gene expression profiles
•Prevention in familial cases –genetic screening, prophylactic mastectomies